Skip to main content

Table 2 The demographic and clinical characteristics of patients at the time of surgery

From: Retrospective analysis of safety and efficacy of enhanced recovery pathways in stage II–III colorectal cancer patients submitted to surgery and adjuvant therapy

Parameters

Cohorts

Comparisons

FTLCO

OTLCO

CSLFO

OSLFO

Surgery

Fast-track laparoscopy

Open fast-track

Conventional laparoscopy

Open conventional

Adjuvant chemotherapy (if required)

8 cycles of capecitabine and oxaliplatin; every 21 days

8 cycles of capecitabine and oxaliplatin; every 21 days

12 cycles of leucovorin, fluorouracil, and oxaliplatin; every 15 days

12 cycles of leucovorin, fluorouracil, and oxaliplatin; every 15 days

Numbers of patients underwent surgeries

125

137

142

138

p value

Age (years)

Minimum

52

51

53

53

0.129

Maximum

67

68

69

69

Mean ± SD

56.22±7.15

57.18±8.19

57.65±6.15

58.45±9.18

Sex

Male

75 (60)

89 (65)

91 (64)

86 (62)

0.848

Female

50 (40)

48 (35)

51 (36)

52 (38)

Body mass index (kg/m2)

Minimum

21

21

21

21

0.904

Maximum

26

26

26

26

Mean ± SD (kg/m2/patient)

24.12±2.13

24.21±2.01

24.32±2.45

24.27±2.45

The American Society of Anesthesiologists status

I

99 (79)

121 (88)

125 (88)

122 (88)

0.219

II

25 (20)

15 (11)

17 (12)

16 (12)

III

1 (1)

1 (1)

0 (0)

0 (0)

Carcinoembryonic antigen (ng/mL/patient)

6.71±1.12

6.52±1.25

6.45±1.35

6.58±1.56

0.441

Carbohydrate antigen 19–9 (ng/mL)

35.12±7.11

36.21±6.15

37.15±8.11

36.15±8.15

0.177

Site

Rectum

38 (30)

41 (30)

41 (28)

40 (29)

0.992

Sigmoid colon

35 (28)

40 (29)

38 (27)

41 (29)

Ascending colon

24 (19)

27 (20)

25 (18)

26 (19)

Descending colon

17 (14)

17 (12)

18 (13)

15 (11)

Transverse colon

11 (9)

12 (9)

20 (14)

16 (12)

Maximum tumor diameter (cm/patient)

4.11±0.18

4.15±0.19

4.13±0.21

4.09±0.25

0.103

Pathologic type

Adenocarcinoma

107 (86)

115 (84)

121 (85)

122 (88)

0.753

Mucinous adenocarcinoma

18 (14)

22 (16)

21 (15)

16 (12)

Differentiation

Well

28 (22)

23 (17)

35 (25)

31 (23)

0.202

Moderate

75 (60)

81 (59)

87 (61)

89 (64)

Poor

22 (18)

33 (24)

20 (14)

18 (13)

Lymph nodes involvement*

14.15±2.11

14.55±1.89

14.35±2.01

14.65±1.95

0.181

Surgical pathological TNM stage (related to AJCC staging system)

I

22 (18)

30 (21)

29 (20)

33 (23)

0.925

II

64 (51)

53 (39)

61 (43)

55 (40)

III

38 (30)

53 (39)

51 (36)

49 (36)

IV

1 (1)

1 (1)

1 (1)

1 (1)

QLQ-C30/CR38 score/patient

79.37±5.11

75.23±6.24

76.46±6.44

71.53±4.55

Clinically insignificant difference**

  1. Categorical and ordinal variables are presented as frequency (percentages) and continuous variables are presented as mean ± standard deviation (SD)
  2. Categorical and ordinal variables were analyzed by the Chi-square test for independence and continuous variables were analyzed by one-way ANOVA
  3. A p value less than 0.05 was considered significant
  4. N/A not applicable, QLQ-C30/CR38 quality of life questionnaires-cancer specific 30/colorectal cancer specific 38, TNM stage Tumor, Node, and Metastasis stage, AJCC staging system American Joint Committee on Cancer staging system
  5. *Mean number of retrieved lymph nodes/patient at pathological examination
  6. **mean difference < 10 score